On 25 and 26 March, the Wallonia Export & Investment Agency will attend the LSX World Congress in Lisbon together with 15 Walloon companies. This event is one of the leading European gatherings in the life sciences sector.
On the occasion of the LSX World Congress, 15 Walloon companies active in biotechnology, medtech and health technologies will take part in the event to meet international partners and investors.
The companies will be present at stand no. 1 of the Wallonia Export & Investment Agency, where visitors will be able to discover Wallonia’s life sciences ecosystem and discuss collaboration and investment opportunities in the region.
The participating companies are:
APMONIA THERAPEUTICS
Apmonia Tx is a biotechnology company pioneering next-generation cancer therapies targeting the tumor microenvironment. Leveraging advanced molecular modeling, AI-driven peptide modeling, and deep expertise in extracellular matrix (ECM) biology, Apmonia Therapeutics develops first-in-class drugs designed to disrupt tumor-stroma interactions and overcome therapeutic resistance.
BIO-SOURCING
BioSourcing is a European biotech company based in Belgium pioneering sustainable largescale production of affordable biotherapeutics, building on the unique features of goat’s milk to offer oral delivery formulation of biologics. Bio-Sourcing has already successfully produced six different monoclonal antibodies, including four for a global pharmaceutical company ranked among the top three in its field. This strategic partnership, which has been in place for over 10 years, has enabled Bio-Sourcing to industrialize its platform and prepare for Phase 1 launch.
Bio-Sourcing is currently raising 30M€ to initiate clinical development and has already secured 10M€ with EICFund.
BIOXODES
Bioxodes is a clinical stage biopharmaceutical company developing novel therapies to disrupt the treatment of stroke, beginning with intracerebral hemorrhage (ICH), which remains one of the deadliest neurological conditions. In September 2025, the company showed the breakthrough potential of its lead candidate BIOX-101 with encouraging Phase 2a data from patients with ICH. Bioxodes has been granted Orphan Drug Designation (ODD) in the US and Europe. The company is now preparing a Phase 2b trial, which could be sufficient for conditional market authorization in the U.S. and Europe, potentially paving the way for BIOX-101 to reach patients as early as end 2030. BIOX-101 offers a unique dual mechanism of action. It reduces clotting without – crucially - increasing bleeding, by targeting Factors XIIa and Xia of the intrinsic coagulation pathway. At the same time, it synergistically dampens harmful inflammation by inhibiting the neutrophils and the neutrophil extracellular traps (NETs). This unique approach is the foundation of an innovative pipeline of drug candidates to treat and prevent (thrombo)inflammatory diseases.
BLOOMLIFE
Bloomlife is an award winning HealthTech company enabling new care delivery models in maternal health to eliminate preventable adverse birth outcomes for moms and babies. The technology used during prenatal checkups has not changed since 1971. Bloomlife is bringing modern connected care to expecting moms leveraging our FDA-cleared prenatal wearable that shifts prenatal care from costly hospital environments to the patient home.
Bloomlife combines connected devices, AI, and virtual provider networks to increase access to care and help doctors earlier predict and manage pregnancy complications. This is made possible by the first patch-based medical wearable designed specifically for pregnant women, that expands access to fetal monitoring to home. The patch is combined with cellular enabled blood pressure and blood glucose monitors to improve screening and management of the most prevalent high-risk conditions.
CONVEYXO
Conveyxo is a Belgian biotech company developing triple A therapies with anti-inflammatory and regenerative properties by leveraging its proprietary technology platform. Conveyxo is solving the bottlenecks of cell & gene therapies with a platform that mimics the body’s natural healing process, leveraging exosomes with anti-inflammatory and regenerative properties, loaded with therapeutic RNAs to accelerate cellular regeneration. Conveyxo has 2 lead candidates in osteoarthritis (OA) and dermatological conditions with an IIT in China early 2027 followed by a CTA in Europe. Conveyxo has 4 follow-on indications (incl. AD, IBD, CKD, Alzheimer’s) via modular RNA payloads
EPICS THERAPEUTICS
Epics Therapeutics is a clinical-stage, private, drug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetics and G-Protein Coupled Receptor (GPCR) mechanisms involved in cancer development. By targeting these mechanisms, Epics Therapeutics aims to translate science into life-changing therapies for patients.
EYED PHARMA
Developing innovative therapeutic solutions for ophthalmic diseases. EyeD Pharma is a clinical stage pharmaceutical company dedicated to improve the life of patients suffering from ophthalmic diseases with innovative sustained release micro-implants and complex therapeutics.
MAN & SCIENCE
Man & Science is a clinical-stage MedTech company developing a minimally invasive cranial neuromodulation platform for patients with severe headache disorders. Their solutions combine a wireless occipital nerve stimulator for preventive therapy and an injectable, navigation-guided microstimulator for on-demand relief, enabling minimally invasive outpatient procedures. With multiple expansion indications and a large underserved market, Man & Science is accelerating development towards commercialization.
QITY
Qity supports lifescience companies in streamlining operations, ensuring compliance, and accelerating innovation. The platform fully integrates:
• iQMS – Quality management system for document control, audits, and compliance
• eBR/MES – Electronic batch records and manufacturing execution, fully integrated with iQMS
• LIMS – Laboratory information management for sample tracking and reporting
• Biobank System – Sample and inventory management, fully connected to iQMS
QUANTOOM BIOSCIENCES
Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode for sequence design and optimization, Ntensify® for RNA production and Ncapsulate® for RNA-LNP formulation. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization.
SAGITTA BIOTECH
Sagitta Biotech is a vaccine platform company developing nextgeneration immunotherapies for infectious diseases and oncology. Its proprietary platform is a hybrid between viral vectors and RNA technologies and is a game-changer in the field. It combines the potency and targeting of viral vectors with the speed and flexibility of RNA, while minimizing the key drawbacks of each.
The result is:
• A highly modular platform for both vaccines (infectious diseases) and targeted therapies (oncology,
autoimmune diseases)
• A single, constant manufacturing process across indications, enabling fast development and scale-up.
• Very attractive economics (low COGS / low CAPEX) thanks to a productive, standardized manufacturing platform
SAMABRIVA
Samabriva develops and industrializes innovative processes for the production of Active Pharmaceutical Ingredients (APIs). Our technology is inspired by a natural mechanism: the cultivation of hairy roots generated from plants and grown in bioreactors to produce the molecules of interest. Our innovative platform makes it possible to produce high-value-added plant-based molecules (alkaloids, polyphenols, cannabinoids, saponins) through a process that secures the supply of active ingredients while reducing by at least 50% carbon footprint and remaining financially competitive.
SANTERO THERAPEUTICS
Santero Therapeutics is a Belgian biotechnology company developing first-in-class medicines for chronic treatment-refractory infections. Founded in 2021 as a spin-off from the Université Libre de Bruxelles (ULB), the company builds on nearly 20 years of foundational research into the mechanisms governing bacterial survival and persistence.
Based at Watson & Crick Hill in Mont-Saint-Guibert, Belgium, Santero's team of scientists and professionals is advancing a platform of RSH enzyme inhibitors with the potential to transform outcomes for patients living with chronic infections that current treatments cannot resolve.
SIGNATUR BIOSCIENCES
Signatur Biosciences makes precision diagnostics more accessible, starting by bringing breast cancer testing within reach for women around the world. Traditional tests used to guide therapy are slow and expensive due to their reliance on complex, centralized facilities. Our tests are designed to seamlessly integrate with standard instruments and workflows already in place in every clinical lab. Our assays empower local labs to deliver results in hours instead of weeks and at a fraction of the cost, significantly increasing accessibility, including for underserved patient populations. Signatur Biosciences is a spinout backed by YCombinator, founded by bioengineers from Imperial College and Oxford University. She set up her first laboratory in Liège, Wallonia.
SPECTRALYS BIOTECH
Spectralys Biotech offers analytical services for structural characterization dedicated to biopharmaceutical products leveraging our sharp expertise in infrared spectroscopy (FTIR), atomic-force microscopy coupled with infrared (AFM-IR), circular dichroism (CD) and hydrogen-deuterium exchange monitored by mass spectrometry (HDX-MS). We originated from an academic laboratory at Université libre de Bruxelles. There, researchers are for example working on structure of membrane and amyloid proteins.
FTIR spectra provide robust fingerprint of biological samples and account not only for the chemical nature of molecules but also for their conformation. They are particularly sensitive to protein and nucleic acid higher-order structure, just like CD spectra. AFM topographies add morphological data to the chemical information from IR spectra. HDX-MS provide information regarding protein conformation, dynamics and binding, at the peptide level resolution. No crystallization is required.
Isabelle Anneet (AWEX)
